Biotech Frontiers: Antibodies, Heart Trials, FDA Moves
Kilder
- BioSpace: World’s First | Mabwell’s 9MW5211 Receives FDA Clearance for Clinical Trial Application - BioSpace
- Biopharmaapac: Mabwell Secures US FDA Clearance For First In Class Autoimmune Antibody 9MW5211 - BioPharma APAC
- Nature: Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial - Nature
- BioSpace: SINOVAC Reports Unaudited First Half of 2025 Financial Results - BioSpace
- wikimedia: Photo by Authors of the study: Matthew J. Landry, PhD, RDN1,2; Catherine P. Ward, PhD, RD1; Kristen M. Cunanan, PhD3; Lindsay R. Durand, MPH, RD1; Dalia Perelman, MS, RDN1; Jennifer L. Robinson, PhD1; Tayler Hennings, MPH1; Linda Koh, PhD, MS, RN1; Christopher Dant, PhD1; Amanda Zeitlin, MPH1; Emily R. Ebel, PhD4; Erica D. Sonnenburg, PhD4; Justin L. Sonnenburg, PhD4,5,6; Christopher D. Gardner, PhD1 / Wikimedia Commons / CC BY 4.0
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.